** Drugmaker Telix Pharmaceuticals Ltd TLX.AX rises as
much as 11.25% to A$4.45, posts biggest intraday percentage gain
since Dec. 11
** Co says its bone marrow conditioning investigational
candidate TLX66 (90Y-besilesomab) has met study objectives in
Patients with AL Amyloidosis, a rare disease where plasma cells
in bone marrow produce abnormal protein which causes organs to
fail urn:newsml:reuters.com:*:nFWN2NB0TW
** TLX says this TLX66 has potential to reduced toxicity
significantly and improve tolerability compared with existing
chemotherapeutic conditioning approaches
** Co says if a complete response is achieved patient can
live 10 yrs+
** Stock hits its highest level since April 7
** About 700,000 shares change hands compared to the 30-day
average volume of about 561,000 shares
** TLX down 5.8% this year, as of last close
(Reporting by Aditya Munjuluru in Bengaluru)
((aditya.srivastsav@thomsonreuters.com))